C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) 是一种细胞渗透性的内源性神经酰胺类似物。C8-Ceramide 具有具有抗增殖特性，能作为化疗试剂。C8-Ceramide 能刺激树突状细胞促进 T 细胞对病毒感染的反应。C8-Ceramide 在体外能轻微地诱导PKC活化。
| 生物活性 | C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent. C8-Ceramide stimulates dendritic cells to promote T cell responses upon virus infections. C8-Ceramide induces slight activation ofprotein kinase (PKC)in vitro[1][2][3][4]. |
| IC50& Target[2][4][5] | |
体外研究
(In Vitro) | C8-ceramide (3 μM; 48 hours) irreversibly reduces tumor-cell proliferation and induces morphological changes[1].
C8-ceramide can induce necrosis-like cell death, but does not induce caspase-dependent cleavage of PARP (biochemical marker of apoptosis) in human cervical tumor cells[1].
C8-ceramide may increase the endogenous ROS level (10-30 μM; 24 hours) by regulating the switch of SOD1 and SOD2, causing the anti-proliferation (10-50 μM; 24 hours), and consequently triggering the apoptosis (10-50 μM; 48 hours) of NSCLC H1299 cells[2].
Cell Viability Assay[1] | Cell Line: | CALO cells, INBL cells, HeLa cells | | Concentration: | 3 μM | | Incubation Time: | 48 hours | | Result: | Markedly reduced the tumor cell number. |
Cell Proliferation Assay[2] | Cell Line: | H1299 cells | | Concentration: | 10 μM, 20 μM, 30 μM, 40 μM, 50 μM | | Incubation Time: | 24 hours | | Result: | Decreased the rate of cellular proliferation in a dose-dependent manner, with an IC50of 22.9 μM. |
Cell Cycle Analysis[2] | Cell Line: | H1299 cells | | Concentration: | 10 μM, 20 μM, 30 μM, 40 μM, 50 μM | | Incubation Time: | 24 hours | | Result: | Caused the G1 arrest. |
Apoptosis Analysis[2] | Cell Line: | H1299 cells | | Concentration: | 10 μM, 20 μM, 30 μM | | Incubation Time: | 24 hours, 48 hours | | Result: | Increased the level of cleaved caspase-3. |
|
体内研究
(In Vivo) | C8-ceramide (0.1 mg/kg; intranasal administration) induces more robust CD8+and CD4+T cell responses to viral infections in virus infected mice[3].
| Animal Model: | C57BL/6 mice, with lymphocytic choriomeningitis virus infected[3] | | Dosage: | 0.1 mg/kg | | Administration: | Intranasal administration | | Result: | Increased the CD8+T cell response to influenza in the lungs. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | -20°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |
| 溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(234.91 mM) *"≥" means soluble, but saturation unknown. 配制储备液 | 1 mM | 2.3491 mL | 11.7456 mL | 23.4913 mL | | 5 mM | 0.4698 mL | 2.3491 mL | 4.6983 mL | | 10 mM | 0.2349 mL | 1.1746 mL | 2.3491 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (stored under nitrogen)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 |
m.cnreagent.com